Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Director William D. Waddill sold 8,500 shares of the stock in a transaction dated Friday, January 11th. The shares were sold at an average price of $14.77, for a total value of $125,545.00. Following the completion of the transaction, the director now owns 46,500 shares of the company’s stock, valued at $686,805. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of ARWR traded down $0.13 during mid-day trading on Friday, reaching $14.87. 1,181,373 shares of the company were exchanged, compared to its average volume of 2,029,443. Arrowhead Pharmaceuticals Inc has a 52 week low of $4.77 and a 52 week high of $22.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.37 and a quick ratio of 6.37. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -22.88 and a beta of 1.96.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, December 11th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.05. Arrowhead Pharmaceuticals had a negative return on equity of 57.18% and a negative net margin of 337.32%. The company had revenue of $11.26 million during the quarter, compared to the consensus estimate of $3.73 million. As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals Inc will post 1.49 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Great West Life Assurance Co. Can acquired a new stake in Arrowhead Pharmaceuticals during the second quarter worth approximately $106,000. Stratos Wealth Partners LTD. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter worth approximately $123,000. Meeder Asset Management Inc. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter worth approximately $129,000. Macquarie Group Ltd. acquired a new stake in Arrowhead Pharmaceuticals during the second quarter worth approximately $151,000. Finally, BlueMountain Capital Management LLC acquired a new stake in Arrowhead Pharmaceuticals during the second quarter worth approximately $188,000. Institutional investors own 60.45% of the company’s stock.
Several equities analysts have commented on the company. Chardan Capital reiterated a “buy” rating and issued a $24.50 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 17th. Cantor Fitzgerald set a $24.00 target price on Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 11th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $25.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 4th. William Blair restated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 17th. Finally, BidaskClub downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Arrowhead Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $21.36.
COPYRIGHT VIOLATION WARNING: This article was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.thestockobserver.com/2019/01/11/arrowhead-pharmaceuticals-inc-arwr-director-william-d-waddill-sells-8500-shares.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
See Also: How to invest in a bear market
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.